Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64.44 USD | +1.64% | +2.53% | +15.38% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- One of the major weak points of the company is its financial situation.
- The firm trades with high earnings multiples: 22.32 times its 2024 earnings per share.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialized REITs
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.38% | 2.75B | C- | ||
+6.55% | 55.76B | A- | ||
-7.26% | 17.64B | A- | ||
-3.18% | 13.29B | A | ||
+1.99% | 7.58B | B | ||
-17.41% | 5.54B | B- | ||
+13.09% | 3.37B | C- | ||
-0.35% | 3.22B | C+ | ||
-2.36% | 3.05B | B+ | ||
-1.43% | 2.8B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NHI Stock
- Ratings National Health Investors, Inc.